|
1
|
Malumbres M and Barbacid M: Mammalian
cyclin-dependent kinases. Trends Biochem Sci. 30:630–641. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bertoli C, Skotheim JM and de Bruin RA:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lim S and Kaldis P: Cdks, cyclins and
CKIs: Roles beyond cell cycle regulation. Development.
140:3079–3093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Swaffer MP, Jones AW, Flynn HR, Snijders
AP and Nurse P: CDK substrate phosphorylation and ordering the cell
cycle. Cell. 167:1750–1761. e1716. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Malumbres M and Barbacid M: To cycle or
not to cycle: A critical decision in cancer. Nat Rev Cancer.
1:222–231. 2001. View
Article : Google Scholar
|
|
6
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Asghar U, Witkiewicz AK, Turner NC and
Knudsen ES: The history and future of targeting cyclin-dependent
kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Senderowicz AM: Flavopiridol: The first
cyclin-dependent kinase inhibitor in human clinical trials. Invest
New Drugs. 17:313–320. 1999. View Article : Google Scholar
|
|
9
|
Santo L, Vallet S, Hideshima T, Cirstea D,
Ikeda H, Pozzi S, Patel K, Okawa Y, Gorgun G, Perrone G, et al:
AT7519, A novel small molecule multi-cyclin-dependent kinase
inhibitor, induces apoptosis in multiple myeloma via GSK-3beta
activation and RNA polymerase II inhibition. Oncogene.
29:2325–2336. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen EX, Hotte S, Hirte H, Siu LL, Lyons
J, Squires M, Lovell S, Turner S, McIntosh L and Seymour L: A Phase
I study of cyclin-dependent kinase inhibitor, AT7519, in patients
with advanced cancer: NCIC Clinical Trials Group IND 177. Br J
Cancer. 111:2262–2267. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen R, Wierda WG, Chubb S, Hawtin RE, Fox
JA, Keating MJ, Gandhi V and Plunkett W: Mechanism of action of
SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic
lymphocytic leukemia. Blood. 113:4637–4645. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heath EI, Bible K, Martell RE, Adelman DC
and Lorusso PM: A phase 1 study of SNS-032 (formerly BMS-387032), a
potent inhibitor of cyclin-dependent kinases 2, 7 and 9
administered as a single oral dose and weekly infusion in patients
with metastatic refractory solid tumors. Invest New Drugs.
26:59–65. 2008. View Article : Google Scholar
|
|
13
|
Tong WG, Chen R, Plunkett W, Siegel D,
Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, et
al: Phase I and pharmacologic study of SNS-032, a potent and
selective Cdk2, 7, and 9 inhibitor, in patients with advanced
chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol.
28:3015–3022. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Trovesi C, Manfrini N, Falcettoni M and
Longhese MP: Regulation of the DNA damage response by
cyclin-dependent kinases. J Mol Biol. 425:4756–4766. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Esashi F, Christ N, Gannon J, Liu Y, Hunt
T, Jasin M and West SC: CDK-dependent phosphorylation of BRCA2 as a
regulatory mechanism for recombinational repair. Nature.
434:598–604. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Finn K, Lowndes NF and Grenon M:
Eukaryotic DNA damage checkpoint activation in response to
double-strand breaks. Cell Mol Life Sci. 69:1447–1473. 2012.
View Article : Google Scholar
|
|
17
|
Johnson N, Cai D, Kennedy RD, Pathania S,
Arora M, Li YC, D'Andrea AD, Parvin JD and Shapiro GI: Cdk1
participates in BRCA1-dependent S phase checkpoint control in
response to DNA damage. Mol Cell. 35:327–339. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Laoukili J, Alvarez M, Meijer LA, Stahl M,
Mohammed S, Kleij L, Heck AJ and Medema RH: Activation of FoxM1
during G2 requires cyclin A/Cdk-dependent relief of autorepression
by the FoxM1 N-terminal domain. Mol Cell Biol. 28:3076–3087. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alvarez-Fernández M, Halim VA, Krenning L,
Aprelia M, Mohammed S, Heck AJ and Medema RH: Recovery from a
DNA-damage-induced G2 arrest requires Cdk-dependent activation of
FoxM1. EMBO Rep. 11:452–458. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
21
|
O'Brien J, Wilson I, Orton T and Pognan F:
Investigation of the Alamar Blue (resazurin) fluorescent dye for
the assessment of mammalian cell cytotoxicity. Eur J Biochem.
267:5421–5426. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dimri GP, Lee X, Basile G, Acosta M, Scott
G, Roskelley C, Medrano EE, Linskens M, Rubelj I and Pereira-Smith
O: A biomarker that identifies senescent human cells in culture and
in aging skin in vivo. Proc Natl Acad Sci USA. 92:9363–9367. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arisan ED, Obakan P, Coker-Gurkan A,
Calcabrini A, Agostinelli E and Unsal NP: CDK inhibitors induce
mitochondria-mediated apoptosis through the activation of polyamine
catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.
Curr Pharm Des. 20:180–188. 2014. View Article : Google Scholar
|
|
24
|
Mohapatra S, Chu B, Zhao X, Djeu J, Cheng
JQ and Pledger WJ: Apoptosis of metastatic prostate cancer cells by
a combination of cyclin-dependent kinase and AKT inhibitors. Int J
Biochem Cell Biol. 41:595–602. 2009. View Article : Google Scholar
|
|
25
|
Sparreboom A, de Jonge MJ and Verweij J:
The use of oral cytotoxic and cytostatic drugs in cancer treatment.
Eur J Cancer. 38:18–22. 2002. View Article : Google Scholar
|
|
26
|
Rixe O and Fojo T: Is cell death a
critical end point for anticancer therapies or is cytostasis
sufficient? Clin Cancer Res. 13:7280–7287. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kodym E, Kodym R, Reis AE, Habib AA, Story
MD and Saha D: The small-molecule CDK inhibitor, SNS-032, enhances
cellular radiosensitivity in quiescent and hypoxic non-small cell
lung cancer cells. Lung Cancer. 66:37–47. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Raghavan P, Tumati V, Yu L, Chan N,
Tomimatsu N, Burma S, Bristow RG and Saha D: AZD5438, an inhibitor
of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell
lung carcinoma cells. Int J Radiat Oncol Biol Phys. 84:e507–e514.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Storch K and Cordes N: The impact of CDK9
on radiosensitivity, DNA damage repair and cell cycling of HNSCC
cancer cells. Int J Oncol. 48:191–198. 2016. View Article : Google Scholar
|
|
30
|
Tewari KS, Sill MW, Long HJ III, Penson
RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao
MM, et al: Improved survival with bevacizumab in advanced cervical
cancer. N Engl J Med. 370:734–743. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Monk BJ and Tewari KS: Evidence-based
therapy for recurrent cervical cancer. J Clin Oncol. 32:2687–2690.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li H, Wu X and Cheng X: Advances in
diagnosis and treatment of metastatic cervical cancer. J Gynecol
Oncol. 27:e432016. View Article : Google Scholar : PubMed/NCBI
|
